Related Experiment Videos
Metformin: a new oral biguanide
R K Campbell1, J R White, B A Saulie
1College of Pharmacy, Washington State University, Pullman, USA.
Clinical Therapeutics
|May 1, 1996
Summary
Metformin is an oral anti-hyperglycemic agent for non-insulin-dependent diabetes mellitus (NIDDM). It effectively lowers blood glucose and lipids without causing weight gain or hypoglycemia, making it a valuable treatment option.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Metformin is a biguanide and an oral anti-hyperglycemic agent.
- It is widely used for managing non-insulin-dependent diabetes mellitus (NIDDM).
Purpose of the Study:
- To review the efficacy and safety of metformin in NIDDM management.
- To highlight metformin's role as a first-line agent, especially for obese and hyperlipidemic patients.
Main Methods:
- Review of existing literature on metformin's pharmacological actions and clinical use.
- Analysis of its effects on glucose and lipid metabolism.
- Comparison with other anti-diabetic agents like sulfonylureas and insulin.
Main Results:
- Metformin primarily reduces hepatic glucose production and enhances peripheral insulin sensitivity.
- It demonstrates comparable glycemic control to sulfonylureas, effective in monotherapy or combination.
- Metformin does not cause weight gain or hypoglycemia when used alone and may reduce serum lipid levels.
Conclusions:
- Metformin is a safe and effective oral anti-diabetic agent for NIDDM.
- Its favorable side effect profile, including lack of weight gain and hypoglycemia, makes it a preferred first-line treatment.
- Combination therapy with sulfonylureas can improve glycemic control in non-responsive patients.